The TP53 Pro72Arg SNP in de novo acute myeloid leukaemia – results of two cohort studies involving 215 patients and 3759 controls

MLA

Eduard Schulz, et al. “The TP53 Pro72Arg SNP in de Novo Acute Myeloid Leukaemia – Results of Two Cohort Studies Involving 215 Patients and 3759 Controls.” British Journal of Haematology, vol. 181, Jan. 2017, pp. 148–51. EBSCOhost, https://doi.org/10.1111/bjh.14527.

APA

Eduard Schulz, Claudia Dill, Sybille Hofer, Gerhard Ehninger, Wilfried Renner, Ridhima Lal, Jan Moritz Middeke, Peter Schlenke, Britt-Sabina Petersen, Franz Quehenberger, Karin Lind, Johannes Schetelig, Gerald Hoefler, Heinz Sill, & Friedrich Stölzel. (2017). The TP53 Pro72Arg SNP in de novo acute myeloid leukaemia – results of two cohort studies involving 215 patients and 3759 controls. British Journal of Haematology, 181, 148–151. https://doi.org/10.1111/bjh.14527

Chicago

Eduard Schulz, Claudia Dill, Sybille Hofer, Gerhard Ehninger, Wilfried Renner, Ridhima Lal, Jan Moritz Middeke, et al. 2017. “The TP53 Pro72Arg SNP in de Novo Acute Myeloid Leukaemia – Results of Two Cohort Studies Involving 215 Patients and 3759 Controls.” British Journal of Haematology 181 (January): 148–51. doi:10.1111/bjh.14527.